Cargando…
U94 alters FN1 and ANGPTL4 gene expression and inhibits tumorigenesis of prostate cancer cell line PC3
BACKGROUND: Insensitivity of advanced-stage prostate cancer to androgen ablation therapy is a serious problem in clinical practice because it is associated with aggressive progression and poor prognosis. Targeted therapeutic drug discovery efforts are thwarted by lack of adequate knowledge of gene(s...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2005
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1200560/ https://www.ncbi.nlm.nih.gov/pubmed/15972109 http://dx.doi.org/10.1186/1475-2867-5-19 |
_version_ | 1782124887388717056 |
---|---|
author | Ifon, Ekwere T Pang, Alan LY Johnson, Warren Cashman, Kathleen Zimmerman, Sharon Muralidhar, Sumitra Chan, Wai-Yee Casey, John Rosenthal, Leonard Jason |
author_facet | Ifon, Ekwere T Pang, Alan LY Johnson, Warren Cashman, Kathleen Zimmerman, Sharon Muralidhar, Sumitra Chan, Wai-Yee Casey, John Rosenthal, Leonard Jason |
author_sort | Ifon, Ekwere T |
collection | PubMed |
description | BACKGROUND: Insensitivity of advanced-stage prostate cancer to androgen ablation therapy is a serious problem in clinical practice because it is associated with aggressive progression and poor prognosis. Targeted therapeutic drug discovery efforts are thwarted by lack of adequate knowledge of gene(s) associated with prostate tumorigenesis. Therefore there is the need for studies to provide leads to targeted intervention measures. Here we propose that stable expression of U94, a tumor suppressor gene encoded by human herpesvirus 6A (HHV-6A), could alter gene expression and thereby inhibit the tumorigenicity of PC3 cell line. Microarray gene expression profiling on U94 recombinant PC3 cell line could reveal genes that would elucidate prostate cancer biology, and hopefully identify potential therapeutic targets. RESULTS: We have shown that stable expression of U94 gene in PC3 cell line inhibited its focus formation in culture, and tumorigenesis in nude mice. Moreover gene expression profiling revealed dramatic upregulation of FN 1 (fibronectin, 91 ± 16-fold), and profound downregulation of ANGPTL 4 (angiopoietin-like-4, 20 ± 4-fold) in U94 recombinant PC3 cell line. Quantitative real-time polymerase chain reaction (QRT-PCR) analysis showed that the pattern of expression of FN 1 and ANGPTL 4 mRNA were consistent with the microarray data. Based on previous reports, the findings in this study implicate upregulation of FN 1 and downregulation of ANGPTL 4 in the anti tumor activity of U94. Genes with cancer inhibitory activities that were also upregulated include SERPINE 2 (serine/cysteine protease inhibitor 2, 7 ± 1-fold increase) and ADAMTS 1 (a disintegrin-like and metalloprotease with thrombospondin type 1 motif, 7 ± 2-fold increase). Additionally, SPUVE 23 (serine protease 23) that is pro-tumorigenic was significantly downregulated (10 ± 1-fold). CONCLUSION: The dramatic upregulation of FN 1 and downregulation of ANGPTL 4 genes in PC3 cell line stably expressing U94 implicate up-regulation of FN 1 and downregulation of ANGPTL 4 in anti tumor activity of U94. Further studies are necessary to determine functional roles of differentially expressed genes in U94 recombinant PC3 cell line, and hopefully provide leads to potential therapeutic targets in prostate cancer. |
format | Text |
id | pubmed-1200560 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2005 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-12005602005-09-09 U94 alters FN1 and ANGPTL4 gene expression and inhibits tumorigenesis of prostate cancer cell line PC3 Ifon, Ekwere T Pang, Alan LY Johnson, Warren Cashman, Kathleen Zimmerman, Sharon Muralidhar, Sumitra Chan, Wai-Yee Casey, John Rosenthal, Leonard Jason Cancer Cell Int Primary Research BACKGROUND: Insensitivity of advanced-stage prostate cancer to androgen ablation therapy is a serious problem in clinical practice because it is associated with aggressive progression and poor prognosis. Targeted therapeutic drug discovery efforts are thwarted by lack of adequate knowledge of gene(s) associated with prostate tumorigenesis. Therefore there is the need for studies to provide leads to targeted intervention measures. Here we propose that stable expression of U94, a tumor suppressor gene encoded by human herpesvirus 6A (HHV-6A), could alter gene expression and thereby inhibit the tumorigenicity of PC3 cell line. Microarray gene expression profiling on U94 recombinant PC3 cell line could reveal genes that would elucidate prostate cancer biology, and hopefully identify potential therapeutic targets. RESULTS: We have shown that stable expression of U94 gene in PC3 cell line inhibited its focus formation in culture, and tumorigenesis in nude mice. Moreover gene expression profiling revealed dramatic upregulation of FN 1 (fibronectin, 91 ± 16-fold), and profound downregulation of ANGPTL 4 (angiopoietin-like-4, 20 ± 4-fold) in U94 recombinant PC3 cell line. Quantitative real-time polymerase chain reaction (QRT-PCR) analysis showed that the pattern of expression of FN 1 and ANGPTL 4 mRNA were consistent with the microarray data. Based on previous reports, the findings in this study implicate upregulation of FN 1 and downregulation of ANGPTL 4 in the anti tumor activity of U94. Genes with cancer inhibitory activities that were also upregulated include SERPINE 2 (serine/cysteine protease inhibitor 2, 7 ± 1-fold increase) and ADAMTS 1 (a disintegrin-like and metalloprotease with thrombospondin type 1 motif, 7 ± 2-fold increase). Additionally, SPUVE 23 (serine protease 23) that is pro-tumorigenic was significantly downregulated (10 ± 1-fold). CONCLUSION: The dramatic upregulation of FN 1 and downregulation of ANGPTL 4 genes in PC3 cell line stably expressing U94 implicate up-regulation of FN 1 and downregulation of ANGPTL 4 in anti tumor activity of U94. Further studies are necessary to determine functional roles of differentially expressed genes in U94 recombinant PC3 cell line, and hopefully provide leads to potential therapeutic targets in prostate cancer. BioMed Central 2005-06-22 /pmc/articles/PMC1200560/ /pubmed/15972109 http://dx.doi.org/10.1186/1475-2867-5-19 Text en Copyright © 2005 Ifon et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Primary Research Ifon, Ekwere T Pang, Alan LY Johnson, Warren Cashman, Kathleen Zimmerman, Sharon Muralidhar, Sumitra Chan, Wai-Yee Casey, John Rosenthal, Leonard Jason U94 alters FN1 and ANGPTL4 gene expression and inhibits tumorigenesis of prostate cancer cell line PC3 |
title | U94 alters FN1 and ANGPTL4 gene expression and inhibits tumorigenesis of prostate cancer cell line PC3 |
title_full | U94 alters FN1 and ANGPTL4 gene expression and inhibits tumorigenesis of prostate cancer cell line PC3 |
title_fullStr | U94 alters FN1 and ANGPTL4 gene expression and inhibits tumorigenesis of prostate cancer cell line PC3 |
title_full_unstemmed | U94 alters FN1 and ANGPTL4 gene expression and inhibits tumorigenesis of prostate cancer cell line PC3 |
title_short | U94 alters FN1 and ANGPTL4 gene expression and inhibits tumorigenesis of prostate cancer cell line PC3 |
title_sort | u94 alters fn1 and angptl4 gene expression and inhibits tumorigenesis of prostate cancer cell line pc3 |
topic | Primary Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1200560/ https://www.ncbi.nlm.nih.gov/pubmed/15972109 http://dx.doi.org/10.1186/1475-2867-5-19 |
work_keys_str_mv | AT ifonekweret u94altersfn1andangptl4geneexpressionandinhibitstumorigenesisofprostatecancercelllinepc3 AT pangalanly u94altersfn1andangptl4geneexpressionandinhibitstumorigenesisofprostatecancercelllinepc3 AT johnsonwarren u94altersfn1andangptl4geneexpressionandinhibitstumorigenesisofprostatecancercelllinepc3 AT cashmankathleen u94altersfn1andangptl4geneexpressionandinhibitstumorigenesisofprostatecancercelllinepc3 AT zimmermansharon u94altersfn1andangptl4geneexpressionandinhibitstumorigenesisofprostatecancercelllinepc3 AT muralidharsumitra u94altersfn1andangptl4geneexpressionandinhibitstumorigenesisofprostatecancercelllinepc3 AT chanwaiyee u94altersfn1andangptl4geneexpressionandinhibitstumorigenesisofprostatecancercelllinepc3 AT caseyjohn u94altersfn1andangptl4geneexpressionandinhibitstumorigenesisofprostatecancercelllinepc3 AT rosenthalleonardjason u94altersfn1andangptl4geneexpressionandinhibitstumorigenesisofprostatecancercelllinepc3 |